about
Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cellsThe RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cellsRole of sorafenib in the treatment of advanced hepatocellular carcinoma: An updateRoles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityThe selectivity of protein kinase inhibitors: a further updateUse of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structureFinding the needle in the haystack: why high-throughput screening is good for your health.Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondNovel small molecule Raf kinase inhibitors for targeted cancer therapeuticsIdentification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK bindingRas history: The saga continues.Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors.RAIN-Droplet: a novel 3D in vitro angiogenesis modelInhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.Targeted therapy in melanoma.Controlling destiny through chemistry: small-molecule regulators of cell fate.Melanoma genetics and the development of rational therapeutics.Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAF.HIF-1alpha: a valid therapeutic target for tumor therapySmall-molecule inhibitors of the ERK signaling pathway: Towards novel anticancer therapeutics.Thyroid cancer: current molecular perspectives.High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies.Targeting the cancer kinome through polypharmacology.Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenibNutlin-3 enhances sorafenib efficacy in renal cell carcinomaRAS Interaction with PI3K: More Than Just Another Effector PathwayV600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitorsIdentification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinaseBAY 43-9006 inhibition of oncogenic RET mutants.Ras/Raf signalling and emerging pharmacotherapeutic targets.Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyMultiple model-informed open-loop control of uncertain intracellular signaling dynamicsDrugging the undruggable RAS: Mission possible?Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials.Small-molecule inhibitors of signal transduction pathways in leukemia therapeutics: how to assess selectivity for malignant signals.Molecular targets for the treatment of juvenile myelomonocytic leukemia.
P2860
Q24300674-BB2BCF32-9220-4DED-9B40-CD77E0F52423Q24519206-3A204B7E-7EAB-42AF-A230-4F05CE385488Q24619987-D345929E-10BB-4F7F-B2EA-352F3ECD84B2Q24645668-5D7576C4-9C54-4C6C-94B2-1ACDEFADCFF5Q24652600-30F30BFC-DE1E-48F2-8788-F437AAB5EBAEQ24654622-3E64290F-59D6-41E2-9304-9F70A0955810Q24797025-113FE4F9-BE7E-4981-8EA0-7401CA387445Q24802613-156B6B6E-A010-40F7-9DC4-5E141157F928Q27026323-E7E8EC55-D8DF-4522-A584-EF9FB4CDC472Q28265862-B396DCF6-7D82-45E1-899D-07181F613EFFQ28648013-A98060E7-2F2B-492D-94B6-41F1AB05EF91Q30404024-E4C2C8E1-CF2A-4544-9537-E30C24C038F5Q30489704-F7513F39-06C7-463B-827A-DA9686A1EF6BQ30579854-E17D27BA-EDAC-4110-96E3-B140416B4FC8Q31115129-3CEBCE04-C688-4267-A84C-69AE6D329A85Q33514138-8397D92F-2C53-4064-88E1-02A7042F1DAAQ33573107-A768179E-0C7E-4890-9186-DBA570359585Q33593482-23F68BF3-C0F3-4C1D-9A51-D0CDA38C33F7Q33726956-E79774B0-B850-4FDD-9BBC-099B01E4D51EQ33732613-19A4062E-B189-4150-BAB2-F2B2AA2C88C0Q33746822-24EE3C5C-C47D-447D-91F8-5E52644291EBQ33756524-6CC9F5CF-03D9-4869-BDDA-4C9FE6A8025AQ33760910-70D944AE-F07E-492D-8DDA-D968B918A791Q33765623-4FFF7CB5-A79D-4C54-B55B-C5C96BDD1B86Q33893019-FD44F86C-A282-4AF1-A0A2-9E8B43EDD819Q34036032-CE048CD5-4A8A-4FF9-9BDA-F156C028FDB8Q34127380-98E982A7-DFC5-45C9-91FD-2127B9A3D2C5Q34202692-CB458A02-F6EC-4C2F-B108-96396AF8B0C5Q34248395-61557D65-AB3D-466A-8C4B-B060E9A7CD23Q34407252-B09BF7D4-FA87-4EDB-B39E-8F19BC23D045Q34565246-D69F563A-CA9E-49B4-BF00-38CF25421F5CQ34660771-F91D06CF-5D4F-4F8A-B625-937B96272B72Q34678882-D51EF359-7F24-409B-ACD2-EC24F67F5109Q35086690-6D0CE034-082F-4F3D-8B99-ABEF058D589BQ35145197-771D79B9-0024-42DA-963B-8623C53AEE82Q35163434-1977EDE1-9A76-4B37-874B-A6A90E62C874Q35166852-D1834758-FB45-4A97-BA9F-7522D485FD88Q35190181-AE75F11C-CECB-420A-A581-6C8D8D0378CBQ35217401-199FB6C9-77A6-4FE0-A912-14AF224368C1Q35579349-FCC19727-A5C7-4380-A995-E2D721ED262D
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Discovery of a novel Raf kinase inhibitor.
@ast
Discovery of a novel Raf kinase inhibitor.
@en
Discovery of a novel Raf kinase inhibitor.
@nl
type
label
Discovery of a novel Raf kinase inhibitor.
@ast
Discovery of a novel Raf kinase inhibitor.
@en
Discovery of a novel Raf kinase inhibitor.
@nl
prefLabel
Discovery of a novel Raf kinase inhibitor.
@ast
Discovery of a novel Raf kinase inhibitor.
@en
Discovery of a novel Raf kinase inhibitor.
@nl
P2093
P356
P1476
Discovery of a novel Raf kinase inhibitor.
@en
P2093
P304
P356
10.1677/ERC.0.0080219
P577
2001-09-01T00:00:00Z